Selected articles
Articles for label Drösslerová Marie are displayed.. Show all articles
KRAS mutations in non‑small cell lung cancer and options of treatment
02/2020 MUDr. Marie Drösslerová; MUDr. Libor Havel
KRAS (Kirsten rat sarcoma viral oncogene homolog) mutations are the most frequently oncogene aberrations in non-small cell lung cancer (NSCLC). KRAS-mutated NSCLC represents a heterogeneous subgroup because there are different KRAS subtypes, mutations and comutations. It results in different biological behavior of the tumor and its response to treatment. A large majority of patients with KRAS mutations have short-term survival. Trials for targeted treatment have failed. Immunotherapy is the most promising treatment for some patients with KRAS-mutated NSCLC. A very hopeful is an experimental cancer drug AMG 510 which is tested in phase 1/2 clinical trial.
ENTIRE ARTICLE
KRAS (Kirsten rat sarcoma viral oncogene homolog) mutations are the most frequently oncogene aberrations in non-small cell lung cancer (NSCLC). KRAS-mutated NSCLC represents a heterogeneous subgroup because there are different KRAS subtypes, mutations and comutations. It results in different biological behavior of the tumor and its response to treatment. A large majority of patients with KRAS mutations have short-term survival. Trials for targeted treatment have failed. Immunotherapy is the most promising treatment for some patients with KRAS-mutated NSCLC. A very hopeful is an experimental cancer drug AMG 510 which is tested in phase 1/2 clinical trial.
A rare case of choroidal metastasis in ALK‑positive NSCLC that responds to crizotinib
05/2019 MUDr. Marie Drosslerová, MUDr. Libor Havel
Targeted therapy enables patients with non-small cell lung cancer (NSCLC) with driver mutations prolongation of overall survival and improvement quality of life compared to chemotherapy. Crizotinib is one of biological drugs. It is a tyrosine kinase inhibitor targeting ALK (anaplastic lymphoma kinase) gene rearrangement. Crizotinib is indicated for the first-line treatment of adults with ALK positive advanced NSCLC and for the treatment of adults with previously treated ALK positive advanced NSCLC. It is also indicated for the treatment of ROS1 positive advanced NSCLC. Crizotinib has a good safety profile and tolerability. Our article describes a clinical case report of ALK positive advanced NSCLC patient with rare choroidal metastasis that responds to crizotinib. Vision of our patient improved with crizotinib. The quality of life was definitely better.
ENTIRE ARTICLE
Targeted therapy enables patients with non-small cell lung cancer (NSCLC) with driver mutations prolongation of overall survival and improvement quality of life compared to chemotherapy. Crizotinib is one of biological drugs. It is a tyrosine kinase inhibitor targeting ALK (anaplastic lymphoma kinase) gene rearrangement. Crizotinib is indicated for the first-line treatment of adults with ALK positive advanced NSCLC and for the treatment of adults with previously treated ALK positive advanced NSCLC. It is also indicated for the treatment of ROS1 positive advanced NSCLC. Crizotinib has a good safety profile and tolerability. Our article describes a clinical case report of ALK positive advanced NSCLC patient with rare choroidal metastasis that responds to crizotinib. Vision of our patient improved with crizotinib. The quality of life was definitely better.